What we do Welcure Drugs & Pharmaceuticals Ltd manufactures bulk drugs, drug intermediates, and pharmaceutical formulations including tablets and syrups, serving healthcare sectors in India. |
Founded in 1,992 |
Market share - |
Problem solved Provides essential and diverse pharmaceutical products including antibiotics and pediatric formulations, addressing healthcare needs and drug availability. |
Top clients or who we serve Pharmaceutical companies, healthcare providers, and government undertakings; operates in B2B and B2C markets. |
Key management - |
Our journey and innovations Since 1992, expanded product range, launched multiple drugs, obtained ISO certifications, and formed international collaborations including a JV with a US company. |
Where we operate Primarily India, with export orders from Thailand and other international markets. |
Top products or what we offer Bulk drugs like ampicillin and trimethoprim, pediatric and veterinary drugs, formulations including tablets, capsules, syrups, and drug intermediates like 6-APA. |
Top brands WELSTAP, X-CLOX, ETHAMBUTOL, RIFA-Z, CETIRIZIN, NORTIN; recognized for product acceptance and market presence. |
Raw materials needed Chemical compounds for bulk drugs and pharmaceutical intermediates. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue largely derived from ongoing pharmaceutical sales; mix of recurring and project-based income. |
Our industry position Established player in Indian pharmaceuticals with growing export sourcing business and diversified product portfolio. |
Financial highlights FY25 revenue Rs. 26.46 crore with net profit Rs. 2.17 crore; turnaround from prior losses; improving financial health. |
Geographical revenue split Primarily domestic sales in India; export sourcing orders increasing from Thailand and other markets. |
Order book Export sourcing mandates worth over Rs. 517 crore signed with overseas clients in FY25. |
Whats driving growth Expansion into pediatric and veterinary drugs, new product launches, collaborations, export deals, and improved marketing strategies. |
Our future plans Increase capacity, expand product lines including ointments and syrups, and strengthen export sourcing business. |
Our green promise - |
Our people and values Strong board governance with diverse directors; emphasis on compliance, ethics, and employee training on workplace policies. |
Key challenges ahead Managing financial risks, regulatory compliance, verification of loans and inventories, and maintaining sustainable growth. |
Interesting facts First Indian company with double US accreditation for ISO 9002; acts as exclusive agent for unique Russian medicine Stevioside. |
Risks and strategy Address financial and audit discrepancies through process improvements; focus on governance; diversify to mitigate market and regulatory risks. |
